G. Gorzegno

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

INCIDENCE OF SKELETAL COMPLICATIONS IN PATIENTS WITH BONE METASTATIC PROSTATE CANCER AND HORMONE REFRACTORY DISEASE: PREDICTIVE ROLE OF BONE RESORPTION AND FORMATION MARKERS EVALUATED AT BASELINE

Alfredo Berruti, Luigi Dogliotti, Raffaella Bitossi et al. · The Journal of Urology · 2000 · 209 citations

p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.

Alberto Bottini, Alfredo Berruti, Alessandra Bersiga et al. · PubMed · 2000 · 123 citations

Preoperative Chemotherapy, Breast Oncology, Chemoprevention Strategy +18

Multimodal management of stages III–IVa malignant thymoma

S. Bretti, Alfredo Berruti, C Loddo et al. · Lung Cancer · 2003 · 119 citations

Surgical Oncology, Medicine, Multimodal Management +4

Differential Patterns of Bone Turnover in Relation to Bone Pain and Disease Extent in Bone in Cancer Patients with Skeletal Metastases

Alfredo Berruti, Luigi Dogliotti, G. Gorzegno et al. · Clinical Chemistry · 1999 · 110 citations · Full text